Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Clifton

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.
MMWR. Morbidity and Mortality Weekly Report|March 4, 2021
SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital - New York City, April 2020Guy T Clifton, Rituparna Pati, Florian Krammer, et al.
Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
Journal of Surgical Oncology|October 6, 2023
Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing mattersFranklin A Valdera, Anne E O'Shea, Todd R Smolinsky, et al.
Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.
MMWR. Morbidity and Mortality Weekly Report|March 4, 2021
SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital - New York City, April 2020Guy T Clifton, Rituparna Pati, Florian Krammer, et al.
Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
Journal of Surgical Oncology|October 6, 2023
Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing mattersFranklin A Valdera, Anne E O'Shea, Todd R Smolinsky, et al.
Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Pageof 8